Nextgen Biomed Ltd (NXGN.TA)
ILA 60.3
(-9.19%)
ILA 60.3
(-9.19%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 6.8 Million | 3.58 Million | 2.83 Million | 1.32 Million | 1.24 Million | 1.21 Million |
| Selling, General and Administrative Expenses | 4.45 Million | 2.03 Million | 2.48 Million | 1.32 Million | 1.24 Million | 1.14 Million |
| Research and Development Expenses | 796 Thousand | 455 Thousand | 351 Thousand | - | - | 65 Thousand |
| Other Expenses | 1.55 Million | -4.98 Million | - | - | - | - |
| Cost and Expenses | 6.8 Million | 3.58 Million | 2.83 Million | 1.32 Million | 1.24 Million | 1.21 Million |
| Operating Income | -6.8 Million | -9.32 Million | -2.83 Million | -1.32 Million | -1.24 Million | -1.21 Million |
| Interest Expense | - | 64 Thousand | 22 Thousand | 1000.00 | 1000.00 | 59 Thousand |
| Income Tax Expense | - | 799 Thousand | 305 Thousand | 29 Thousand | -2000.00 | -6000.00 |
| Earnings before Tax | -14.2 Million | -8.58 Million | -2.55 Million | -1.29 Million | -1.21 Million | -1.27 Million |
| Net Income | -14.19 Million | -8.57 Million | -2.55 Million | -1.29 Million | -1.21 Million | -1.26 Million |
| Earnings Per Share Basic | -1.95 | -0.20 | -0.06 | -0.04 | -0.04 | -0.04 |
| Earnings Per Share Diluted | -1.95 | -0.20 | -0.06 | -0.04 | -0.04 | -0.04 |
| Weighted Average Shares Outstanding | 7.26 Million | 43.34 Million | 39.67 Million | 32.51 Million | 28.99 Million | 28.99 Million |
| Weighted Average Shares Outstanding (Diluted) | 7.26 Million | 43.34 Million | 39.67 Million | 32.51 Million | 28.99 Million | 28.99 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -5.24 Million | -8.5 Million | -2.52 Million | -1.29 Million | -1.24 Million | -1.21 Million |
| Earnings Before Tax Margin | - | - | - | - | - | - |
| Breakdown | 2023 FY | 2023 Q2 | 2022 FY | 2022 Q4 | 2022 Q2 | 2021 FY |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | 5000.00 | 2000.00 | - |
| Gross Profit | - | - | - | -5000.00 | -2000.00 | - |
| Operating Expenses | 14.17 Million | - | 3.58 Million | 1.86 Million | 1.71 Million | 2.83 Million |
| Selling, General and Administrative Expenses | - | - | - | 1.57 Million | 1.54 Million | - |
| Research and Development Expenses | - | - | - | 293 Thousand | 162 Thousand | - |
| Other Expenses | - | - | -4.98 Million | - | - | - |
| Cost and Expenses | 14.17 Million | - | 3.58 Million | 1.86 Million | 1.71 Million | 2.83 Million |
| Operating Income | -5.24 Million | - | -9.32 Million | -1.86 Million | -1.71 Million | -2.83 Million |
| Interest Expense | - | - | 64 Thousand | - | - | 22 Thousand |
| Income Tax Expense | -8000.00 | - | 799 Thousand | -2000.00 | -6000.00 | 305 Thousand |
| Earnings before Tax | -14.2 Million | - | -8.58 Million | -6.91 Million | -1.66 Million | -2.55 Million |
| Net Income | -14.19 Million | - | -8.57 Million | -6.91 Million | -1.65 Million | -2.55 Million |
| Earnings Per Share Basic | - | - | - | -0.96 | -0.23 | - |
| Earnings Per Share Diluted | - | - | - | -0.96 | -0.23 | - |
| Weighted Average Shares Outstanding | 7.26 Million | - | 43.34 Million | 7.22 Million | 7.22 Million | 39.67 Million |
| Weighted Average Shares Outstanding (Diluted) | 7.26 Million | - | 43.34 Million | 7.22 Million | 7.22 Million | 39.67 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | - | - | - | -1.86 Million | -1.71 Million | - |
| Earnings Before Tax Margin | - | - | - | - | - | - |
EQGPF
0RWM
1214
FTAI
UNISON
TOBII